Advanced Search

Study Preview



Study Title and Description

The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.



Key Questions Addressed
1 KQ 1: What are the benefits and harms of nonpharmacological treatments of UI in women, and how do they compare with each other? KQ 2: What are the benefits and harms of pharmacological treatments of UI in women, and how do they compare with each other? KQ 3: What are the comparative benefits and harms of nonpharmacological versus pharmacological treatments of UI in women? KQ 4: What are the benefits and harms of combined nonpharmacological and pharmacological treatment of UI in women?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
Author Chughtai B., Forde JC., Buck J., Asfaw T., Lee R., Te AE., Kaplan SA.
Country Department of Urology, Weill Cornell Medical College/New York Presbyterian Hospital, NY, USA bic9008@med.cornell.edu.
Year 2016
Numbers Pubmed ID: 26883688

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: All studies
Arms
Number Title Description Comments
1 fesoterodine + estrogen
  • Comments Comments (
    0
    ) |
2 fesoterodine
  • Comments Comments (
    0
    ) |

Design Details
Question... Follow Up Answer Follow-up Answer
Study type RCT
  • Comments Comments (
    0
    ) |
Country/countries U.S.
  • Comments Comments (
    0
    ) |
Funding source Industry funded/industry provided materials
  • Comments Comments (
    0
    ) |
Inclusion criteria postmenopausal women with a history of overactive bladder symptoms for at least 3 months and at least one urgency incontinence episode per 24 h
  • Comments Comments (
    0
    ) |
Exclusion criteria evidence of chronic urologic inflammation, uncontrolled narrow angle glaucoma, recurrent urinary tract infection, significant stress incontinence, a partner with sexual dysfunction, an anatomic disorder of sexual function, a recent major gynaecological surgery, abnormal cervical smear results, history of gynaecological malignancy, and/or uncontrolled hypertension
  • Comments Comments (
    0
    ) |
UI type
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
100
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Age 55.4
  • Comments Comments (
    0
    ) |
mean
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
40.7, 66.6
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Men included 0
  • Comments Comments (
    0
    ) |
Special populations 23
  • Comments Comments (
    0
    ) |
100
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Race 23
  • Comments Comments (
    0
    ) |
100
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Notes
  • Comments Comments (
    0
    ) |
Did participants fail previous treatment? Not reported/unclear
  • Comments Comments (
    0
    ) |
Study years nd
  • Comments Comments (
    0
    ) |
Trial name (if given)
  • Comments Comments (
    0
    ) |
Does this paper cite a previous paper from the same study?
  • Comments Comments (
    0
    ) |


Baseline Characteristics
Question fesoterodine + estrogen fesoterodine Total Comments
AnswerFollow-up AnswerFollow-up AnswerFollow-up
Participant flow 11 12
  • Comments Comments (
    0
    ) |
9 9
  • Comments Comments (
    0
    ) |
2 3
  • Comments Comments (
    0
    ) |
discontinued discontinued
  • Comments Comments (
    0
    ) |
Notes No data entered.



Results & Comparisons

No Results found.

Quality Dimensions
Dimension Value Notes Comments
RCT:.....Adequate generation of a randomized sequence Low RoB
  • Comments Comments (
    0
    ) |
RCT:.....Allocation concealment Unclear RoB not reported
  • Comments Comments (
    0
    ) |
RCT:.....Blinding of PATIENTS High RoB
  • Comments Comments (
    0
    ) |
RCT.....Intention-to-treat-analysis High RoB
  • Comments Comments (
    0
    ) |
ALL.....Blinding of OUTCOME ASSESSORS (or "DOUBLE BLIND") High RoB
  • Comments Comments (
    0
    ) |
ALL.....Incomplete results data (attrition bias) Low RoB
  • Comments Comments (
    0
    ) |
ALL....Group similarity at baseline (selection bias) Unclear RoB no baseline data given
  • Comments Comments (
    0
    ) |
ALL.....Compliance with interventions Low RoB
  • Comments Comments (
    0
    ) |
NRCS.....Patients in different intervention groups selected in an equivalent manner
  • Comments Comments (
    0
    ) |
NRCS....Baseline differences between groups accounted for (Adjusted analysis)?
  • Comments Comments (
    0
    ) |
ALL.....Other issues
  • Comments Comments (
    0
    ) |
ALL....Were interventions adequately described? Yes
  • Comments Comments (
    0
    ) |

Quality Rating
Guideline Used Overall Rating